India, Oct. 30 -- Bengaluru, India, October 30, 2026 - OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) today announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a 'Voluntary Action Indicated' (VAI) classification. The report follows an inspection of the facility conducted from June 22 to June 30, 2026.
Commenting on the development, Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma, said, "We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This inspection outcome reflects our continued commitment to maintaining high standards ...